dr. reddy's labs glp-1 receptor agonist medications Dr Launches Oral Semaglutide in India A Comprehensive Review of the

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

Improved blood sugar regulation and metabolic health

Eat less, move more is not a long-term weight management solution

Pharmacovigilance analyses identified disproportionate reporting signals for dyspnoea and asthma-like events, particularly with exenatide, using the reporting odds ratio (ROR 2.14, 95% CI 1.882.43

Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption